Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Danirixin - GSK

Drug Profile

Danirixin - GSK

Alternative Names: 1325756; DNX; GSK-1325756; GSK-1325756H; GSK1325756B

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer GSK
  • Class Anti-inflammatories; Antivirals; Piperidines; Small molecules; Sulfones
  • Mechanism of Action Interleukin 8B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Influenza virus infections
  • Discontinued Chronic obstructive pulmonary disease

Most Recent Events

  • 28 Oct 2020 No recent reports of development identified for preclinical development in Influenza-virus-infections in United Kingdom (IV, Infusion)
  • 15 May 2020 Efficacy and adverse events data from a phase II trial in Chronic obstructive pulmonary disease presented at the 116th International Conference of the American Thoracic Society (ATS-2020)
  • 24 Jan 2019 GlaxoSmithKline terminates a phase II trial in Chronic Obstructive Pulmonary Disease in United kingdom(NCT03250689)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top